Despite Widespread Obesity, Diet Pills Face Tough Scrutiny

Want to lose weight? The U.S. Food and Drug Administration might have some advice in mind: Do it the old-fashioned way.

The agency, after pressuring Abbott Laboratories to withdraw its diet drug Meridia because of serious potential side effects, including heart attack and stroke, is cautiously reviewing other proposed weight-loss medications. One explanation for the apparent reluctance to approve diet drugs, The Wall Street Journal reports, is that the agency is concerned about medications that, even if effective, eventually may cause problems for patients who take them indefinitely.

That might be an especially important consideration, the Journal suggests, because many obese people likely to take the drugs aren’t currently suffering health problems.

Last week, the FDA rejected the weight-loss drug lorcaserin, from Arena Pharmaceuticals Inc. and Eisai Co., over concerns about limited effectiveness and tumors found in rats in laboratory studies. The FDA is scheduled to make a decision regarding Vivus Inc.’s diet pill Qnexa later this week, but it faces an uphill battle, given that an agency advisory panel in July recommended against approval.

Contrave, from Orexigen Therapeutics Inc., will go before an FDA panel in December.

Although Qnexa has had the most promising results, with patients achieving a 13 to 14 percent reduction in body mass, it too has raised concerns about health risks, including heart palpitations and suicidal thoughts. Contrave, which has yet to be reviewed, is a combination of addiction-treating naltrexone along with the antidepressant bupropion, which has been associated with heart and psychiatric side effects.

Rodman & Renshaw analyst Elemer Piros told the Journal that the recent FDA panel discussions make it clear that the drugs must be as safe as diet and exercise.

Related Posts:

FDA Moves Against Meridia and a Second Weight-Loss Aid
Heart Risks Often Are Key in Decisions to Ban Drugs, Analysis Finds

Print Print  

Like what we're doing? We'd appreciate your support.

One comment to “Despite Widespread Obesity, Diet Pills Face Tough Scrutiny”

  1. Michelle Obama and Obesity

    Having lived though the phen-fen era, caution seems appropriate. Maybe Michelle and Walmart will get us over the tipping point.

Leave a comment